Introduction We investigated plasma proteomic markers of astrocytopathy, brain
degeneration, plasticity, and inflammation in sporadic early-onset versus late-onset …

To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has
largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic …

Aims The association between the pathological features of AD and dementia is stronger in
younger old persons than in older old persons suggesting that additional factors are …

Background Increasing evidence supports the use of plasma biomarkers of
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …

Background In vitro and animal studies have linked neuroinflammation to Alzheimer's
disease (AD) pathology. Studies on markers of inflammation in subjects with mild cognitive …

Objective To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). Design
Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker …

Alzheimer's disease (AD) characterization has progressed from being indexed using clinical
symptomatology followed by neuropathological examination at autopsy to in vivo signatures …

Introduction Plasma markers have been reported to be associated with brain amyloid
burden, tau pathology, or neurodegeneration. We aimed to evaluate whether plasma …

Peripheral biomarkers of Alzheimer's disease (AD) reflecting early neuropathological
change are critical to the development of treatments for this condition. The most widely used …

Following the development of the first methods to measure the core Alzheimer's disease
(AD) cerebrospinal fluid (CSF) biomarkers total-tau (T-tau), phosphorylated tau (P-tau) and …